yahoo_financeOriginal article
NeOnc Technologies to Host Investor Conference Call to Discuss Topline Phase 2a Results for Intranasal NEO100 in Recurrent IDH1-Mutant High-Grade Glioma
Phase 2NEO100Neutral
AI Analysis
Summary
NeOnc Technologies announced it will host an investor conference call to discuss topline Phase 2a results for intranasal NEO100 in recurrent IDH1-mutant high-grade glioma. The article is a preliminary announcement without disclosed results or specific dates.
Clinical Trial Data
Phase
2a
Importance:5/10
Sentiment:
0.00
Phase 2aNEO100IntranasalIDH1-MutantHigh-Grade GliomaInvestor Conference
Related Companies
Read the original article
Published by yahoo_finance on August 10, 2026 1:42 PM